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Abstract
We conducted a systematic review and network meta-analysis to determine the comparative
efficacy of antibiotics used to control bovine respiratory disease (BRD) in beef cattle on fee-
dlots. The information sources for the review were: MEDLINE®, MEDLINE In-Process and
MEDLINE® Daily, AGRICOLA, Epub Ahead of Print, Cambridge Agricultural and
Biological Index, Science Citation Index, Conference Proceedings Citation Index – Science,
the Proceedings of the American Association of Bovine Practitioners, World Buiatrics
Conference, and the United States Food and Drug Administration Freedom of Information
New Animal Drug Applications summaries. The eligible population was weaned beef cattle
raised in intensive systems. The interventions of interest were injectable antibiotics used at
the time the cattle arrived at the feedlot. The outcome of interest was the diagnosis of BRD
within 45 days of arrival at the feedlot. The network meta-analysis included data from 46 stud-
ies and 167 study arms identified in the review. The results suggest that macrolides are the
most effective antibiotics for the reduction of BRD incidence. Injectable oxytetracycline effect-
ively controlled BRD compared with no antibiotics; however, it was less effective than macro-
lide treatment. Because oxytetracycline is already commonly used to prevent, control, and
treat BRD in groups of feedlot cattle, the use of injectable oxytetracycline for BRD control
might have advantages from an antibiotic stewardship perspective.
Introduction
Rationale
Bovine respiratory disease complex (BRD) is the most economically significant disease of feedlot
cattle (Apley, 2006; Miles, 2009; Taylor et al., 2010). Putative causal organisms include
Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, Mycoplasma bovis, bovine
herpes virus, bovine viral diarrhea virus, bovine respiratory syncytial virus, and parainfluenza
type 3 virus. Although vaccination against the putative causal organisms is frequently used to
help control BRD, antibiotics are also given to beef cattle when the cattle first arrive at feedlots
(United States Department of Agriculture Animal and Plant Health Inspection Service
Veterinary Services Centers for Epidemiology andAnimal Health April, 2013).With growing con-
cern about antibiotic use in the beef industry, it is essential to fully understand the efficacy of anti-
biotics to ensure that they are being used prudently (Landers et al., 2012; Martin et al., 2015;White
House Forum Spotlights Antibiotic Overuse in Medicine and Food Production, 2015).
Drug efficacy is one of the many factors that must be considered when selecting antibiotics
for use in a given setting. Evidence of the comparative efficacies of the available antibiotics is
essential for prudent selection. If veterinarians know that multiple antibiotic regimes have
comparable efficacies, then factors such as cost and antibiotic stewardship considerations
can be used to differentiate among comparable products.
Systematic review and pairwise meta-analysis of randomized controlled trials yield the best
evidence of the comparative efficacies of different treatments under field conditions (Wellman
and O’Connor, 2007; Baptiste and Kyvsgaard, 2017). It is often the case, however, that an
insufficient number of trials are available for a pairwise meta-analysis. In such situations, net-
work meta-analysis can be used to borrow information from the network of available evidence
in order to obtain estimates of comparative efficacy (Taylor et al.,
2010; Jackson et al., 2017; Lin et al., 2019). Several network
meta-analyses have been conducted to evaluate the comparative
efficacies of antibiotics for the treatment and control of BRD in
beef production (O’Connor et al., 2013, 2016; Abell et al.,
2017). Although the assessment of bias is an important compo-
nent of a systematic review, an approach to describe the contribu-
tions of multiple studies to biases in estimates resulting from
systematic reviews was not available until recently (CINeMA:
Confidence in Network Meta-Analysis [Software] 2017).
Objectives
We sought to comprehensively assess the evidence for the effica-
cies of the different antibiotics used to control BRD in feedlot cat-
tle in the USA using the network of trials currently available in the
literature. In addition, we sought to update the approach used to
assess the risk of bias in our estimates of efficacy.
Methods
Protocol and registration
The protocol for this studywas developed before the review, approved
by the funding agency advisory board and the funding agency staff,
andpostedonline forpublic access (https://works.bepress.com/annet-
te_oconnor/82/ and http://www.syreaf.org). Some minor modifica-
tions of the approved protocol were made to facilitate a more
comprehensive systematic review and are described as needed. This
review was reported using the approach described previously for net-
work meta-analyses (Hutton et al., 2015).
Eligibility criteria
Population
The eligible population was defined as weaned cattle raised for
meat production in intensive systems that put animals at risk of
BRD. Eligible cattle were housed in feedlot settings, that is, as
groups of penned cattle receiving rations rather than grazing on
pasture. Calves explicitly described as veal or dairy calves were
excluded from consideration. Calves raised on pasture, such as
pre-conditioning and stocker calves, also were excluded.
Interventions
The interventions of interest were the injectable antibiotics listed in
Table 1. The interventions were used in the early stages of the feedlot
period to control the incidence of BRD. Any injectable antibiotic
regime was eligible for inclusion; however, for reporting purposes,
we only report on the efficacy of regimes that are licensed for use
in the USA. All of the included antibiotics are licensed by the
United States Food and Drug Administration (FDA) for the purpose
of disease control, so the purpose of each antibiotic usewas defined as
control rather than treatment or prevention. The animals that
received the antibiotics were a mixture of animals that were clinically
sick but did not display detectable symptoms of BRD and animals
that were disease free but at risk of developing BRD. Studies that
assessed the efficacy of antibiotics used to treat cattle that had been
previously diagnosed with BRD were not relevant to the review.
Some studies explicitly removed detectably ‘sick’ animals from the
study population at the time the animals arrived at the feedlot. The
FDA considers such a study design to be an assessment of BRD con-
trol rather thanBRDprevention, given the imperfect sensitivity of the
methods used to detect BRD when the cattle arrive at the feedlot
(Timsit et al., 2016). Although the FDA uses the term ‘control,’ we
were unable to find an explicit definition of disease control used by
the FDA. The American Veterinary Medical Association (AVMA)
defines control as follows: Antimicrobial control of disease (syno-
nym: metaphylaxis):
• Control is the administration of an antimicrobial to an individ-
ual animal with a subclinical infection to reduce the risk of the
infection becoming clinically apparent, spreading to other tis-
sues or organs, or being transmitted to other individuals.
• On a population basis, control is the use of antimicrobials to
reduce the incidence of infectious disease in a group of animals
that already has some individuals with evidence of infectious
disease or evidence of infection (American Veterinary
Medical Association, 2017).
The antibiotic use in the studies included in our review corre-
sponds to the second item in the AVMA definition. Furthermore,
the synonym given by the AVMA for antimicrobial disease con-
trol, metaphylaxis, is defined by the European Union
Commission as follows: term ‘metaphylaxis’, refers to the admin-
istration of the product at the same time to a group of clinically
healthy (but presumably infected) in-contact animals, to prevent
them from developing clinical signs, and to prevent further spread
of the disease (European Union Commission, 2015), which is con-
sistent with the AVMA definition. Much of the debate about what
is control or prevention in the USA and Europe occurred after
many of the studies in our review were conducted and reported.
Therefore, the authors of the studies might have been uncertain
about the distinctions between prevention and control, which
are now important considerations but were not always so, and
the peer-review process might likewise have been relatively
unconcerned about ensuring that the precise purpose of the anti-
biotic use (i.e. prevention or control) was clarified.
The outcome thatwe extracted from the studieswas the cumulative
incidence of initial treatment for diagnosed BRD within the first 45
days that the cattle were on the feedlot. The choice of 45 days was
somewhat arbitrary compared to other possible intervals such as 30
or 60 days. However, the goal was to capture early occurrences of
BRD that might be impacted by the use of antibiotics at the time the
cattle arrived on the feedlot. Secondaryoutcomeswere BRD incidence
and BRDmortality over the entire time the cattle were on the feedlot.
The metrics extracted from the studies were prioritized as follows:
• First priority metric: Estimates of efficacy that adjusted for the
clustering of feedlot populations, such as adjusted risk ratios,
adjusted odds ratios, or the arm-level probability of an event
obtained by transformation of the adjusted odds ratio. If the
study was conducted in only one pen, the adjustment was not
considered necessary.
• Second priority metric: Estimates of efficacy that did not adjust
for the clustering of feedlot populations, such as unadjusted risk
ratios, unadjusted odds ratios, or the arm-level probability of an
event obtained by transformation of the unadjusted odds ratio.
• Third priority metric: Raw arm-level data, such as the number of
animals with BRD and the number of animals allocated and ana-
lyzed in the group.
If the first priority metric was reported, the lower priority metrics
were not extracted. Our rationale for the prioritization was that the
meta-analysis should use an adjusted summary effect, as most rele-
vant studies are randomized trials conducted in clustered
populations.
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Study designs
Studies relevant to the review had to contain at least one compari-
son group (active comparator or placebo) and at least one group
that received one of the injectable antibiotic regimens considered
an on-label use to control BRD in feedlot cattle (Table 1). Each
study had to describe how the investigator selected the allocation
to distinguish it from a cohort study. Challenge studies were not
eligible. Although the approved protocol stated that only rando-
mized studies were to be included, studies that reported using ‘sys-
tematic randomization’ or pure systematic (e.g. alternation)
allocation were included, because they were considered trials.
The potential for bias associated with non-random allocation
methods was captured by the risk-of-bias assessment. Studies
Table 1. Antibiotic regimens extracted from studies identified by the systematic review
Antibiotic regimen Short name
Label-dose
regimen Abbreviation
Ceftiofur crystalline free acid, 6.6 mg kg−1, SC in ear, SID, 1 dose CeftiofurCFA (pinna) Yes CCFA_P
Danofloxacin, 8 mg kg−1, SC, 1 dose Danofloxacin Yes DAN
Enrofloxacin, 7.5 mg kg−1, SC, 1 dose Enrofloxacin Yes ENR
Florfenicol, 40 mg kg−1, SC, 1 dose Florfenicol Yes FLO
Gamithromycin, 6 mg kg−1, SC, 1 dose Gamithromycin Yes GAM
Oxtetracycline 10–40 mg kg−1, SC,IM 1 dose Oxytetracycline_1 Yes OXY_1
Oxytetracycline, 20 mg kg−1, SC, 2 doses, 48 h apart Oxytetracycline_2 Yes OXY_2
Oxytetracycline, 30 mg kg−1, IM, 1 dose Oxytetracycline_300 Yes OXY_300
Penicillin 4000 units lb−1 Penicillin Yes PEN
Placebo Placebo Yes PLC
Tildipirosin, 4 mg kg−1, SC, 1 dose Tildipirosin Yes TILD
Tilmicosin, 10 mg kg−1 SC, 1 dose Tilmicosin Yes TIL
Trimethoprim-sulfadoxine IM Trimethoprim-sulfadoxine Yes TMS
Tulathromycin, 2.5 mg kg−1 SC, 1 dose Tulathromycin Yes TUL
Albon-SR, SRS, 12.5 g 200 lb−1, oral OR_Albon No OR_Albon
AS-700, 350 mg chlortetracycline, 350 mg sulfamethazine OR_AS_700 No OR_AS_700
AS-700, 350 mg chlortetracycline, 350 mg sulfamethazine OR_AS_700 No OR_AS_700
Bovatec, 200 mg, in-feed ± LA-200 4.5 cc cwt−1, injected, 1 dose OR_OXY No OR_OXY
CCFA_P; 8 days later Draxin, tulathromycin, 2.5 mg kg−1, SC OL_CCFA_TUL No OL_CCFA_TUL
Chlortetracycline (CTC) 1 gm 100 lbs−1 OR_CTC No OR_CTC
Dihydrostreptomycin sulfate (3.3 mg lb−1) OL_DHS No OL_DHS
IBR + penicillin + dihydrostreptomycin OL_MULTI1 No OL_MULTI1
IBR + penicillin + dihydrostreptomycin OL_MULTI2 No OL_MULTI2
IBR vaccine only OL_VAC No OL_VAC
LA-200, oxytet, 10 mg lb−1, IM; Albon-SR, sulfa, 12.5 g 200 lb−1, oral OL_MULT3 No OL_MULT3
LA-200, oxytet, 10 mg lb−1, IM; Albon-SR, sulfa, 12.5 g 200 lb−1, oral OL_MULT4 No OL_MULT4
Liquamycin LA-200 (9 mg lb−1) + sulfamethazine (Spanbolet II) OL_MULTI5 No OL_MULTI5
Longicil S (4000 units penicillin lb−1 + 3.3 mg lb−1 dihydrostreptomycin) OL_MULTI6 No OL_MULTI6
Neo-Terramycin 50–50, 1.4 g neomycin, 2 g terramycin OL_MULTI7 No OL_MULTI7
Nitric oxide, 32–40 ml, intranasal OL_NO No OL_NO
Oxytetracycline, 0.5 g 45.4 kg−1, IM, 2 doses, 14 or 21 days apart OL_OXY No OL_OXY
Stress Formula, bovine TF, 700 mg, oral syringe, top dress 4 days OL_MULTI8 No OL_MULTI8
Terramycin (4.5 ml 100 lb−1) + 2 Sustain III sulfa boluses OL_MULTI9 No OL_MULTI9
Tilmicosin, 10 mg kg−1, SC, 2 doses, 72 h apart OL_TIL No OL_TIL
Tilmicosin, 4.5 ml 100 lb−1, SC, neck, 1 dose, M. haemolytica 2 ml, SC, neck OL_TIL_VAC No OL_TIL_VAC
Tulathromycin, 1.1 ml 100 lb−1; Aureomycin, 10 mg lb−1, top-dress ± AS-700, 350
mg head−1, topdress
OR_TUL No OR_TUL
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with cluster-based or individual-based allocation were eligible for
inclusion.
Report characteristics
In addition to the eligibility criteria described in the PICOS ele-
ments described above, the included studies had to have their
full texts available in English. Peer review was not an eligibility
criterion, as information from conference proceedings was eligible
for inclusion. No country or date restrictions were applied.
Information sources
The electronic databases used for the literature search were
MEDLINE, MEDLINE In-Process and MEDLINE Daily, Epub
Ahead of Print, Cambridge Agricultural and Biological Index
(CABI), Science Citation Index, Conference Proceedings
Citation Index Science, and AGRICOLA. MEDLINE sources
were searched using the Ovid interface. AGRICOLA was searched
via Proquest. The remainder of the databases were searched using
the Iowa State University Web of Science interface.
The proceedings of the American Association of Bovine
Practitioners (1997–2017) and the World Buiatrics Conference
(1997–2017) were searched for relevant citations. We also
searched the FDA Freedom of Information (FOI) New Animal
Drug Applications (NADA) summaries online (https://animal-
drugsatfda.fda.gov/adafda/views/#/foiDrugSummaries). European
Medicines Authority (EMA) data were not searched because nei-
ther the European Public Assessment Report (EPAR) nor its
product information provides data similar to the FDA FOI
NADA summaries. Finally, we searched the bibliographies of
the reviews that were identified in the initial screening for add-
itional studies (Abell et al., 2017; Baptiste and Kyvsgaard,
2017). The search results were uploaded to EndNoteX9
(Clarivate Analytics, Philadelphia, PA, USA), and duplicate
results were identified and removed. The records were then
uploaded to the systematic review management software
DistillerSR (Evidence Partners Inc., Ottawa, ON, USA) and exam-
ined further to exclude duplicate records.
Search
The searches conducted are summarized in Supplementary Tables
S1–S5. The search approach was modified for the different data-
base or information source as appropriate.
Selection of studies relevant to the review
The first round of study selection was based on abstracts and
titles. The second round of study selection, for relevance to the
meta-analysis, was based on the full text of the articles. The ques-
tions used for each level of screening are provided in the protocol
available online (https://works.bepress.com/annette_{o}connor/
82/). Some minor modifications for clarity were made to the ques-
tions in the protocol, as described in the text accompanying the
Supplementary materials S1 and S12. For example, an additional
answer option was included that allowed reviewers to identify
reviews that were potentially relevant to the project.
Two reviewers conducted a pre-test of the first 100 abstracts
identified in the search to ensure that the questions were clear
and consistently understood. The questions and their wording
were revised during the pre-test phase until there was agreement
that they captured the required information. Studies were
excluded if both reviewers responded ‘no’ to either Q1 or Q2 in
Table S2. If at least one reviewer responded ‘yes’ to each question,
the study was advanced to the full-text assessment, which
determined if the studies met the eligibility criteria for inclusion
in the meta-analysis. Two reviewers conducted a pre-test on the
first five full texts that were advanced to the full-text assessment
to again ensure that the questions were clear and consistently
understood. The questions and their wording were revised further
during the second pre-test phase until there was agreement that
they captured the required information. During the data extrac-
tion phase, if disagreements about eligibility occurred, a third
reviewer (AOC) was consulted. As a result of the consultation
process, the final agreement among the reviewers was 100%.
Studies that passed the full-text assessment were included in
the meta-analysis if they contained sufficient data for the log
odds ratio and the standard error of the log odds ratio to be cal-
culated using the prioritized metrics extracted from the study. The
criteria for inclusion in the meta-analysis are described further in
the statistical analysis section.
Data collection process
Systematic review management software (DistillerSR®, Evidence
Partners, Ontario, Canada) was used to extract data from the
selected studies into the pre-tested forms. Two reviewers inde-
pendently extracted all of the data elements of interest from the
relevant full-text articles. After extraction, any disagreements
were resolved by discussion. If the discussions did not lead to con-
sensus, a third reviewer (AOC) was consulted. The unit of con-
cern for data extraction was the study level, if available. Data
from multi-site studies were extracted at the site level if the rele-
vant information was reported. If investigators combined multiple
sites into a single analysis and only reported the pooled informa-
tion, then the pooled information was extracted. We did not con-
tact the study authors about missing data. If multiple studies were
linked, we used all of the available information and cited the study
that provided the most complete report.
Data items
Items such as the country and year in which the study was con-
ducted, the interventions that were used, and the outcomes that
were measured were extracted at the study level. If baseline char-
acteristics and information about the loss to follow-up were
reported, those were extracted as arm-level data. Other data
extracted at the arm level included the treatments and the results
(based on prioritization). The published protocol, which includes
a list of all items extracted, is available online.
Geometry of the network
Network geometry was assessed using a previously proposed
approach (Salanti et al., 2008). The probability of an inter-species
encounter (PIE) index was calculated using a custom R script.
The PIE index is a continuous variable that decreases in value as
unevenness increases. Values <0.75 can be considered to reflect a
limited diversity of interventions. We also assessed co-occurrence
using the C-score, which is based on a checkerboard analysis and
describes whether particular pairwise comparisons of specific treat-
ments are preferred or avoided within the network (Salanti et al.,
2008). The C-score test was performed using the R package
EcoSimR version 0.1.0 (Gotelli and Entsminger, 2001).
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Risk of bias within individual studies
The risk-of-bias form used for this study was based on the
Cochrane Risk of Bias 2.0 tool for randomized trials. The form
was modified to ensure its relevance to the topic area (Higgins
et al., 2016). The risk-of-bias assessment was conducted at the
outcome level (BRD morbidity and mortality) for the outcome
assessment domain. For the other risk domains, the responses
for BRD morbidity and mortality were considered the same
within a given study. For the purpose of assessing the risk of
bias due to allocation processes, the Cochrane Risk of Bias tool
for individually allocated studies places substantial emphasis on
allocation concealment. It is unclear, however, if that emphasis
is applicable in beef production settings. Therefore, rather than
make an overall bias assessment for bias arising from the alloca-
tion approach, we asked the following three signaling questions:
• SQ 1.1 – Was the allocation sequence random?
• SQ 1.2 – Was the allocation sequence concealed until partici-
pants were recruited and assigned to interventions?
• SQ 1.3 – Were there evident baseline imbalances that suggested
a problem with the randomization process?
For cluster-randomized trials, the first three signaling questions
for bias arising from the allocation approach were also assessed
and presented with the individual-level questions. Two additional
questions related to bias arising from the characteristics of indi-
vidual participants in the cluster-randomized studies were
assessed and presented separately.
• Were all the characteristics of the individual participants likely
to be evenly distributed across the treatment groups?
• Were there any baseline imbalances that suggested differential
identification or recruitment of individual participants between
arms?
If studies within a single citation had different characteristics that
impacted bias, such as loss to follow-up, a risk-of-bias assessment
was made for each study separately. Otherwise, multiple studies
presented within a single citation were considered as a single
set of results.
The other bias domains considered were the following:
(1) Domain 2: Bias arising from deviations from the intended
interventions;
(2) Domain 3: Bias arising from missing outcome data;
(3) Domain 4: Bias arising from the measurement of the out-
come; and
(4) Domain 5: Bias arising from the selection of the reported
outcome.
Summary measures
The baseline risk used to convert the odds ratios to the risk ratio was
obtained using the distribution of the log odds of the placebo group.
The posterior distribution of the mean was N(−0.3759; 1.0323). The
posterior distribution of the standard deviationwasN(1.0059; 0.1392).
Planned method of statistical analysis
The proposed method of statistical analysis has been described in
detail elsewhere (Dias et al., 2010). We used a random-effects
Bayesian model for continuous outcomes. Let b denote the base-
line treatment of the whole network (usually placebo), and let bi
denote the trial-specific baseline treatment of trial i. It could be
the case that b≠ bi. Suppose there are L treatments in a network.
Assume a normal distribution for the continuous measure of the
treatment effects of arm k relative to the trial-specific baseline arm
bi in trial i, yibik, with variance Vibik, such that






), for bi = b,
N(dbk − dbbi , s2bik), for bi = b,
{
where dbk is the treatment effects of k relative to the network base-
line treatment b and s2bik is the between-trial variance. The priors
of dbk and sbik are
dbk  N(0, 10000),
and there is a homogeneous variance assumption that s2bik = s2,
where σ∼U(0, 5). Thus, for L treatments, we have L− 1 priors for
dbl, l∈ {1, …, L}, l≠ b. For l = b, we have dbb = 0.
Handling of multi-arm trials
For multi-arm trials, we assumed that the co-variance between
ujbjk and ujbjk′ was σ
2/2 (Higgins and Whitehead, 1996; Lu and
Ades, 2004). The likelihood of a trial i with ai arms would be
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where the diagonal elements in the variance–covariance matrix
represent the variances of the treatment differences, and the off-
diagonal elements represent the observed variance in the control
arm in trial i, denoted by se2i1. For all studies, the results were con-
verted to log odds ratios for analysis. If the study authors reported
a risk ratio, that was converted back to the log odds ratio using the
reported risk of disease in the placebo group. When the authors
reported the probability of BRD in each treatment arm on the
basis of a model, then that probability was converted back to
the logs odds ratio using a method described elsewhere (Hu
et al., 2019).
Selection of prior distributions in the Bayesian analysis
The prior distributions were originally based on an approach
reported previously (Dias et al., 2011). As in previous models,
we assessed σ∼U(0, 2) and σ∼U(0, 5), and our results suggested
that σ∼U(0, 5) was preferable. We repeated that assessment and
retained the same prior distributions used in the previous models
(O’Connor et al., 2016).
Implementation and output
All posterior samples were generated using a Markov Chain
Monte Carlo (MCMC) simulation implemented with the Just
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Another Gibbs Sampler (JAGS) software (Plummer, 2015). All
statistical analyses were performed using R software (version
3.5.2) (R Core Team, 2015). We fitted the model using JAGS,
an MCMC sampler, by calling JAGS from R through the rjags
package (version 4-8) (Plummer, 2015). Three chains were simu-
lated and the convergence was assessed using Gelman–Rubin
diagnostics. We discarded 5000 ‘burn-in’ iterations based on
our inferences from a further 10,000 iterations. The model output
included all possible pairwise comparisons of the log odds ratios
(for inconsistency assessment), risk ratios (used for comparative
efficacy reporting), and treatment failure rankings (for compara-
tive efficacy reporting).
Assessment of the model fit
The fit of the model was assessed on the basis on the log odds
ratios by examining the residual deviance between the predicted
values from the MTC model and the observed values from each
study (Dias et al., 2010).
Assessment of inconsistency
Network meta-analysis relies on an assumption of consistency
between direct and indirect intervention effects that are distinct
from the usual variation that stems from a random effects
meta-analysis model. For example, if one study compares the dir-
ect effect of treatment A with the effect of treatment B, and
another study compares the efficacies of treatments B and C,
then the (indirect) effect of treatment A relative to the efficacy
of treatment C can be inferred. We used the back calculation
method to assess the consistency assumption (Dias et al., 2010).
We did not rely only on the P-values for the consistency evalu-
ation; instead, we compared the direction and magnitude of the
estimates. We also compared the estimates from the direct and
indirect models and considered the standard deviation of each
estimate. Comparisons in which the direct and indirect estimates
had different signs were further evaluated and discussed.
Risk of bias assessment across studies
To describe the overall quality of the evidence network and the bias
across the studies, we employed a modification of the GRADE
approach for network meta-analysis (Salanti et al., 2014;
Papakonstantinou et al., 2018) using the Confidence in Network
Meta-Analysis (CINEMA) online software (http://cinema.ispm.ch)
(CINeMA: Confidence in Network Meta-Analysis [Software]
2017). CINEMA takes a frequentist approach to the calculation
of treatment effects based on the metafor package in R
(Viechtbauer, 2010). The contribution matrix for the risk of bias
is based on that approach. An equivalent tool using a Bayesian ana-
lysis is not currently available. The system that we used evaluates
within-study bias, across-studies bias, indirectness, imprecision,
heterogeneity, and incoherence. We evaluated and reported the con-
tributions of studies to the within-study bias on the basis of random-
ization and blinding rather than an overall assessment of bias. The
rationale for using that approach was that there is evidence from vet-
erinary science that failure to include randomization and blinding
elements in the study design is associated with larger estimates of
effects, whereas there is no evidence that other elements included
in the Cochrane risk of bias, such as allocation concealment,
introduce any bias in livestock production data (Sargeant et al.,
2009). For randomization, we evaluated the risk of bias as follows:
• ‘Low risk of bias’ refers to studies that reported and provided
evidence of random allocation, identified by a ‘yes’ or ‘probably
yes’ answer to risk-of-bias question Q1.1.
• ‘Unclear risk of bias’ refers to studies that reported random allo-
cation but provided no evidence, identified by a ‘no information
random’ response to risk-of-bias question Q1.1.
• ‘High risk of bias’ refers to studies that used non-random allo-
cation or provided no information about allocation, identified
by a ‘no,’ ‘probably no,’ or ‘no information at all’ response to
risk-of-bias question Q1.1.
We considered proper blinding of caregivers and outcome asses-
sors to be associated with a low risk of bias. If the study authors
mentioned only one of those, we considered it unclear whether or
not there was potential for bias, and if neither was reported, we
considered the potential for bias to be high.
• ‘Low risk of bias’ refers to studies that reported blinding of care-
givers and outcome assessors, identified by a ‘no’ or ‘probably
no’ response to risk-of-bias questions Q 2.2 and Q4.1.
• ‘Unclear risk of bias’ refers to studies that reported blinding of
caregivers and outcome assessors, identified by a ‘no’ or ‘prob-
ably no’ response to risk-of-bias question Q 2.2 or Q4.1, but not
both.
• ‘High risk of bias’ refers to studies that did not fall into the
above two categories.
In CINEMA, indirectness refers to how closely the study popula-
tions resemble the populations in which the intervention is to be
used. Given the narrow eligibility criteria for our meta-analysis,
we did not consider indirectness to be an issue. Accordingly, we
considered the risk of bias due to indirectness to be low in all
of the selected studies. The ability to assess bias across studies
in a network meta-analysis is poorly developed. None of the stud-
ies that we reviewed had a sufficient number of pairs to make an
informative pairwise assessment of small-study effects, so we did
not attempt that assessment. For the assessment of imprecision,
which indicates if the boundaries of the confidence intervals for
the treatment effects could lead to different outcomes, we used
0.8, a clinically important odds ratio that equates to ±0.2231 on
the log scale. We used the same odds ratio to assess heterogeneity.
We did not present the inconsistency analysis from CINEMA,
because that analysis was already conducted as part of the
Bayesian analysis.
Additional analyses
No additional analyses were conducted.
Results
Study selection
The flow of the studies from citation retrieval to inclusion in the
meta-analysis is shown in the PRISMA diagram in Fig. 1. In the
PRISMA diagram, we only show unique relevant citations. Some
citations had multiple trials, multiple arms, or multiple time
periods at which outcomes were reported. Because of the rarity
of the mortality outcome, we deviated from the approved proto-
col and did not analyze that outcome. Eighty-five trials from a
total of 73 citations reported at least one BRD morbidity
outcome.
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Study selection: excluded because of data extraction issues
Seventeen citations had at least one trial in which an arm was
excluded from our meta-analysis because of one of the following
data issues: multiple arms represented the same treatment, there
were zero events in one arm, no extractable data were presented,
there was no P-value or baseline risk available for data conversion,
the treatment regimen was inadequately described, or the treat-
ment was entirely disconnected from the network (Schipper and
Kelling, 1974; Janzen and McManus, 1980; Brown et al., 1989;
van Koevering et al., 1992; Guichon et al., 1993; Galyean et al.,
1995; Montague et al., 1996; Reece and Smith, 1996; Brazle,
1997; Hibbard et al., 2002; Booker et al., 2006; Booker et al.,
2007; Fazzio et al., 2015; Crepieux et al., 2016; Miller et al.,
2016; Timsit et al., 2017a, 2017b; Food and Drug
Administration, 2018f).
Study selection: excluded because of the duration of BRD
assessment
Nineteen trials either did not report the duration of their observa-
tions of BRD incidence or had an observation period longer than
45 days (Schipper and Kelling, 1971; Stokka and Kreikemeier,
1996; Schunich et al., 2002; Cusack, 2004; Step et al., 2007;
Bryant et al., 2008; John et al., 2008; van Donkersgoed et al.,
2008; Corbin et al., 2009; Blasi et al., 2010; van Donkersgoed
and Merrill, 2012; Hendrick et al., 2013; Stegner et al., 2013;
van Donkersgoed and Merrill, 2013a, 2013b; Compiani et al.,
2014; Tennant et al., 2014; Sturgess and Renter, 2017; van
Donkersgoed et al., 2017).
Study selection: included in the meta-analysis
Our meta-analysis included data from 37 citations that described
46 studies in which BRD morbidity was reported within 45 days
of the arrival of the cattle at the feedlot (Lofgreen et al., 1978;
Breeze et al., 1982; Gill et al., 1986; Schumann et al., 1990;
Harland et al., 1991; Schumann et al., 1991; Morck et al., 1993;
Vogel et al., 1998; McClary and Vogel, 1999; Duff et al., 2000;
Frank and Duff, 2000; Glynn et al., 2002; Meeuwse and
Hibbard, 2002; Food and Drug Administration, 2003; Guthrie
et al., 2004; Kilgore et al., 2005; Rooney et al., 2005; Martin
et al., 2007; Benton et al., 2008; Montgomery et al., 2008;
Nickell et al., 2008; Rossi et al., 2010; Baggott et al., 2011;
Gonzalez-Martin et al., 2011; Siddartha et al., 2013; Amrine
et al., 2014; White et al., 2015; DeDonder et al., 2016;
Hanzlicek et al., 2016; Hawley et al., 2016; Regev-Shoshani
et al., 2017; Food and Drug Administration, 2018a, 2018b,
2018c, 2018d, 2018e, 2018f, 2018g).
Presentation of the network structure
The final evidence network used in the meta-analysis represented
46 studies and 167 arms. Some of the arms used treatment regi-
mens that were not labeled for use in the USA but contributed
useful information about variations of regimens of interest. The
antibiotic regimens used in those off-label studies are reported
in Table 1. Four of the included studies were three-arm studies,
and one was a four-arm study. Thirty-four of the studies com-
pared non-active or controlled treatment groups with active treat-
ment groups, whereas the other 12 studies compared multiple
active treatment groups.
Summary of the network geometry
The geometry of the network was sparse, with many regimens
assessed only once. The network was diverse, however, as indi-
cated by the PIE index of 0.84. A PIE index of >0.75 suggests
that a network is diverse, although, as with any threshold, that
is a guideline rather than a strict cut-off for interpretation pur-
poses (Salanti et al., 2008). The conclusion that the network
was diverse is consistent with a visual examination of the network,
which includes a large number of treatments (Fig. 2). The diver-
sity measure considers all treatments included in the
meta-analysis and is bolstered by treatments that were not rele-
vant to the meta-analysis. The C-score was 19.45 (P = 0.43).
The C-score is used to evaluate how random encounters occur
in ecological populations. When used in a network meta-analysis,
the C-score assesses whether or not there are particular pairwise
comparisons that occur more (or less) often than expected if
the pairing is random. Although the P-value suggests that the
pairing was random, visual examination of the network suggests
that researchers had a preference for comparisons that involved
placebo-controlled study arms.
Study characteristics
The descriptive information, including the definitions of success
and the exclusion criteria, about the studies identified in the lit-
erature search is provided in the Supplementary materials
(Table S6). All of the relevant studies, rather than just those
included in the meta-analysis, are listed in Table S6 to show
how the study populations differed between the studies that
were included in the meta-analysis and those that were excluded.
Of particular interest is the baseline conditions applied to the ani-
mals in each study. Some of the studies failed to clearly document
concurrent treatments that were received by the animals, such as
vaccinations, antiparasitic treatments, and antibiotics. Other stud-
ies did provide that information, and some even reported using
in-feed antibiotics concurrently with the injectable antibiotics
for BRD control.
The approaches used to handle the cases of BRD that were
diagnosed at the time the cattle arrived on the feedlot are reported
in Table S7. Many studies failed to clearly describe how those
cases of BRD were handled. The definitions of BRD reported by
the study authors are listed in Table S8. In each instance where
a single citation included multiple studies, the studies used the
same definition of the outcome, so Table S8 is indexed by citation
rather than by study. The definitions of outcomes were generally
consistent and frequently reported.
Individual risk of bias
The results of the risk-of-bias assessments for the studies that
were determined to be relevant to the meta-analysis are shown
in Table S9. The answers to the two additional questions for
the cluster-randomized trials are presented in Table S10.
Synthesis of the results
The final meta-analysis included results from 46 studies. The
measures of convergence from the Bayesian model were within
normal limits. The results of the model are presented in several
ways. Table 4 shows the comparative risk ratios for only the
label-dose regimens. The data are organized so that the event
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is the risk of treatment failure for the treatment listed in the row,
divided by the risk of failure for the treatment listed in the
column. For example, in the first row of the table, all the risk
ratio estimates are >1, meaning that the risk of treatment failure
was higher in the non-active control (NAC) groups for PLC
compared with that in the active treatment groups for each
of the other antibiotics. The upper right-hand quadrant of
Table 4 shows the estimated risk ratio, and the lower quadrant
reports the 95% CI. Estimates of the average ranks of the antibio-
tics in terms of efficacy are provided in Fig. 3, which only
includes the label-dose regimens. The rankings for the label-dose
regimens in the meta-analysis are presented in Table 2. We
excluded the off-label regimens from Fig. 3 because we do not
want to promote the off-label use of antibiotics. Rankings close
to 1 are associated with low rates of treatment failure. There is
considerable overlap in the confidence intervals of the rankings.
The probability distribution of the treatment responses for the
label-dose protocols is presented in the Supplementary materials
(Table S13 and Fig. S1). Also included in the Supplementary
materials is a summary of the probabilities of being ranked
first and last (Table S14) and all possible pairwise probabilities
of being better or worse than other antibiotic regimens in
Table S15.
Exploration of inconsistency
The consistency between the direct and indirect sources of evi-
dence in the final model using 46 studies and 167 arms is reported
in Table 3. In the model, we found no evidence of inconsistency
between the direct and indirect estimates. A potential reason for
that finding is that the small number of studies available for
some comparisons caused the standard deviations for the direct
estimates to be very wide, making it difficult to detect differences
between direct and indirect estimates.
Fig. 3. Ranking plot of relevant treatments. Lower rankings indicate lower incidence
of BRD. Rankings are reported for label-dose regimens only. Abbreviations are
defined in Table 1.
Fig. 2. The network of treatment arms used in the mixed-treatment comparisons meta-analysis. The size of the dot is a relative indicator of the number of arms,
and the width of the lines is a relative indicator of the number of direct comparisons. Abbreviations defined in Table 1.
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Risk of bias across studies
There was an enormous number of possible pairwise comparisons
(i.e. all possible pairs) in the risk-of-bias assessment. Therefore,
we only presented the active-to-active comparisons of on-label
antibiotic regimes (Table S11). The contributions of the included
studies to the risk of bias based on the studies’ randomization sta-
tus are presented in Fig. 4. The contributions based on the studies’
blinding status are presented in Fig. 5. Fewer studies presented a
risk of bias due to randomization issues than presented risks due
to blinding issues. We assumed that all of the studies were free of
bias related to indirectness. For each outcome, a considerable
number of comparisons presented major concerns related to
imprecision, reflecting the large confidence intervals of the risk
ratios resulting from the small number of trials in each compari-
son. Most of the comparisons presented no concerns about bias
due to heterogeneity, which was expected on the basis of the
wide confidence intervals of the risk ratios.
Results of additional analyses
No additional analyses were conducted.
Discussion
Summary of the evidence
The results suggest that the macrolides as a group are the most
effective antibiotics administered to cattle upon arrival at the feed-
lot to control BRD. The evidence for that conclusion is summar-
ized best in the ranking plot (Fig. 3), which shows that the
regimens involving tulathromycin, gamithromycin, tilmicosin,
and tildipirosin are the top-ranked treatments. Ceftiofur had the
next highest ranking, after the macrolides. Those results are con-
sistent with the findings of other reviews of antibiotic use to con-
trol BRD in feedlot cattle (Abell et al., 2017; Baptiste and
Kyvsgaard, 2017). The macrolides are listed as critically important
antibiotics with the highest priority by the World Health
Organization (WHO). Oxytetracycline and florfenicol, also listed
as important antibiotics by the WHO, were less effective than the
macrolides and ceftiofur, although they were more effective than
danofloxacin and enrofloxacin (both of which are critically
important). Many of the comparisons with other regimens in
our meta-analysis are based on only a single study, so confidence
in the pairwise differences is low. Data from the National Animal
Health Monitoring Scheme Antibiotic Use 2017 report indicate
that 14.8% (SE 3.5) of feedlots used injectable antibiotics in
groups of cattle. In that report, ‘treated as a group’ meant that
at least 90% of the cattle in a pen or group were treated with
one or more injectable antimicrobial agent for the purpose of pre-
venting, controlling, or treating a disease outbreak. Injectable oxy-
tetracycline is the antibiotic most commonly used on groups of
cattle on feedlots in the USA (United States Department of
Agriculture Animal and Plant Health Inspection Service
Veterinary Services National Animal Health Monitoring System
May, 2019) (4.8%, SEM 2.5), followed by tulathromycin (2.8%,
SEM 0.8), ceftiofur (2.7%, SEM 1.3), and enrofloxacin (2.4%,
SEM 2.0). In terms of the percentage of cattle treated, rather
than the percentage of feedlots using the antibiotic, the injectable
antibiotic most commonly used in groups of cattle on feedlots was
tulathromycin (4.4%, SEM 0.6), followed by gamithromycin
(2.9%, SEM 0.8). It would be tempting to link those statistics
with the estimates of efficacy from our network meta-analysis
in order to make inferences about prudent antibiotic choices.
That is not feasible, however, because the NAHMS report does
not distinguish among instances of injectable antibiotic use for
prevention, control, and treatment of BRD. Our results suggest
that most of the injectable antibiotics are very effective at reducing
the incidence of BRD during the first 45 days that cattle are on the
feedlot. Although the posterior distributions of the risk ratios were
often wide, as suggested by the credible intervals in Table 4, the
Table 2. Mean ranking by treatment efficacy of antibiotic regimens based on the mixed-treatment comparisons meta-analysis






rank 2.50% 50% 97.5%
Tulathromycin TUL Macrolide CIA 1.44 0.62 1 1 3
Gamithromycin GAM Macrolide CIA 3.25 1.03 2 3 6
Tildipirosin TILD Macrolide CIA 5.26 3.07 1 4 13
Tilmicosin TIL Macrolide CIA 5.43 1.37 3 5 9
CeftiofurCFA (pinna) CCFA_P Cephalosporins (3rd
Generation)
CIA 8.73 2.24 5 9 13
Oxytetracycline_1 OXY_1 Tetracyclines HIA 8.86 2.43 4 9 13
Florfenicol FLO Amphenicols HIA 9.04 2.26 5 9 14
Danofloxacin DAN Quinolones and
fluoroquinolones
CIA 10.07 3.84 3 10 17
Enrofloxacin ENR Quinolones and
fluoroquinolones
CIA 11.12 3.60 4 12 17
Trimethoprim-Sulfadoxine TMS Potentiated
sulfonamides
Not listed 13.91 2.71 7 14 17
Placebo (non-active
control)
PLC NA NA 15.34 1.20 13 15 17
Lower rankings indicate a lower incidence of BRD. World Health Organization categories for medically important antibiotics: Critically Important Antimicrobial (CIA), Highly Important
Antimicrobial (HIA), Important Antimicrobial (IA) (SD, standard deviation).
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means of the posterior distribution of the risk distribution suggest
that apart from sulfamethoxazole and trimethoprim combina-
tions, the injectable antibiotics reduced the risk of BRD within
the first 45 days on the feedlot by 1.5-fold on average compared
with placebo. An alternative way to look at those data is to use
Table S15, which shows that all of the antibiotic regimens have
at least a 0.5 probability of being better than a NAC. Because
the diagnosis of BRD is imperfect, and misclassification would
bias the associations toward the null, the actual efficacy of the
antibiotics is likely even higher than our estimates (White and
Renter, 2009).
Limitations of the body of work
The body of work that informed our literature review was large
and relevant to the North American feedlot populations. In
those characteristics, we believe that the studies met the important
transit assumption of network meta-analysis: that the animals in a
given study would be eligible for the treatments used in other
studies. We did, however, find that lack of replication was an
issue in some of the studies. For many interventions, only one
trial was available. Therefore, estimates of effect sizes were often
based on only one study. As with any scientific investigation,
the value of replication is that it enables the consistency of effect
measurements to be assessed.
Another limitation of the body of work is that the size of the
effect of antibiotic use might change over time, and our time
frame for study retrieval was not restricted. All methods of
research synthesis assume that the network of evidence being
used is static, meaning that the estimates presented in research
reports are valid at the time the research was conducted and in
subsequent years. However, there are a number of published stud-
ies suggesting that the frequency of antimicrobial resistance and
the likelihood of multi-resistant organisms being present in host
populations are growing (DeDonder and Apley, 2015; Anholt
et al., 2017). The evaluation of trends over time in treated animals
is complicated by the association between antibiotic treatment
and the emergence of antimicrobial resistance in diagnostic sam-
ples (Magstadt et al., 2018). When antimicrobials, such as macro-
lides and tetracyclines, are used for both metaphylaxis and
Table 3. Results of the indirect comparison for the consistency assumption
Comparison d(dir) SD(dir) d(MTC) SD(MTC) d(rest) SD(rest) wXY SDwXY P
PLC versus TILD −1.28 2.92 −1.28 0.47 −1.28 0.47 0.00 2.96 1.00
PLC versus DAN −0.66 2.91 −0.65 0.50 −0.64 0.50 −0.02 2.95 1.00
PLC versus ENR −0.53 2.87 −0.51 0.47 −0.51 0.48 −0.02 2.90 1.00
PLC versus TMS −0.03 2.93 −0.15 0.43 −0.15 0.43 0.12 2.96 0.97
PLC versus OL_TIL −1.89 2.91 −1.76 0.50 −1.75 0.51 −0.14 2.95 0.96
PLC versus OL_MULT3 −0.26 2.91 −0.39 0.48 −0.39 0.49 0.14 2.95 0.96
PLC versus TIL −1.24 0.15 −1.18 0.15 2.44 1.12 −3.69 1.13 0.00
PLC versus GAM −1.48 0.39 −1.55 0.18 −1.57 0.21 0.09 0.44 0.84
PLC versus CCFA_P −0.66 0.54 −0.81 0.21 −0.83 0.23 0.17 0.58 0.77
PLC versus TUL −2.21 1.22 −2.01 0.19 −2.00 0.19 −0.21 1.24 0.87
PLC versus FLO −0.70 0.28 −0.77 0.21 −0.87 0.31 0.18 0.42 0.67
PLC versus OXY_1 −0.79 0.85 −0.78 0.31 −0.78 0.33 −0.01 0.91 0.99
PLC versus OR_A −0.28 2.96 −0.37 0.48 −0.38 0.48 0.10 3.00 0.97
TIL versus OL_NO 0.48 2.89 0.50 0.50 0.50 0.51 −0.02 2.93 0.99
TIL versus OL_MULTI8 1.11 2.87 1.10 0.44 1.10 0.44 0.00 2.90 1.00
TIL versus OL_TIL 0.47 2.85 −0.58 0.45 −0.61 0.45 1.08 2.88 0.71
TIL versus CCFA_P 0.26 1.47 0.37 0.19 0.37 0.19 −0.11 1.48 0.94
TIL versus TUL −0.61 1.54 −0.83 0.17 −0.83 0.18 0.22 1.55 0.89
GAM versus CCFA_P 0.26 2.86 0.74 0.20 0.74 0.20 −0.48 2.87 0.87
GAM versus TUL −0.19 1.02 −0.46 0.19 −0.47 0.19 0.28 1.04 0.79
OL_OXY versus OXY_1 −0.04 2.89 −0.05 0.51 −0.05 0.51 0.01 2.94 1.00
TUL versus FLO 1.08 1.63 1.23 0.20 1.23 0.20 −0.15 1.64 0.93
OXY_1 versus TMS −0.50 2.87 0.63 0.38 0.65 0.39 −1.15 2.90 0.69
OXY_1 versus OL_MULT3 −0.27 2.91 0.39 0.42 0.40 0.43 −0.67 2.94 0.82
OXY_1 versus OR_A −0.26 2.89 0.41 0.42 0.42 0.42 −0.68 2.92 0.81
OR_A versus OL_MULT3 0.03 2.82 −0.02 0.48 −0.02 0.49 0.05 2.86 0.99
Posterior means (d) and standard deviations (SD) of the log-odds ratio of treatment effects calculated using direct evidence only (dir), all evidence (MTC), and indirect evidence only (rest).
The treatment on the left is the reference (denominator), and that on the right is the comparator (numerator). w and SD(w) are the inconsistency estimate and standard deviation of the
inconsistency estimate, respectively.
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treatment, the emergence of resistant organisms becomes more
likely (Timsit et al., 2017a, 2017b). For those reasons, estimates
of efficacy reported in older studies might no longer be valid
because of recently emerging resistance, resulting in overestima-
tions of current efficacy. Although it is unclear how the designa-
tion of ‘resistance’ empirically translates to metrics of clinical
efficacy, most of the studies included in our meta-analysis were
conducted early in the use period of the respective drugs and
therefore represent the best-case scenario. If resistance is develop-
ing equally to all of the antibiotics, then the relative estimates of
efficacy are likely still relevant. Alternatively, if resistance to some
antibiotics is developing faster than that to other antibiotics, then
the assumption of equal resistance development is not valid, and
the relative estimates of efficacy have even more uncertainty than
what is captured by research synthesis methods. One argument
against changes in the prevalence of resistance being a major
issue is that estimates derived from network meta-analyses very
closely predict comparative efficacies in trials (O’Connor et al.,
2013, 2016). Indeed, estimates of treatment efficacy for BRD
from older studies were able to very accurately predict the com-
parative efficacies of new drugs (O’Connor et al., 2013, 2016).
For example, for the comparison of gamithromycin (referent)
and tulathromycin, the original model predicted a risk ratio of
re-treatment of 0.54 (95% credible interval 0.27–0.87). In the sub-
sequent randomized controlled trial, the observed risk ratio of
re-treatment was 0.59 (95% confidence interval 0.45–0.78). For
the gamithromycin (referent) and florfenicol comparison, the
observed risk ratio in the randomized trial was 1.17 (95% confi-
dence interval 0.83–1.64), and the estimated risk ratio from the
prior model was 0.84 (95% credibility interval 0.48–1.3). For the
gamithromycin and tilmicosin (referent) comparison, the risk
ratio observed in the randomized trial was 0.99 (95% confidence
interval 0.67–1.47), and the risk ratio estimated from the prior
model was 1.09 (95% credible interval 0.64–1.79). If the data
from older studies did not accurately represent current efficacy
because of the emergence of resistant bacteria, those estimates
would not be expected to be so close to the observed values.
Assessment of error and bias is part of any good systematic
review. The extent of random error is expressed by the credible
intervals on the risk ratios and the rankings. The wide credible
intervals in our results are mainly due to low replication within
the studies. As shown in Fig. 2, for many antibiotic regimes,
there is little publicly available information that could be incorpo-
rated into our meta-analysis. Large feedlot companies, veterinary
consultants, and pharmaceutical companies likely have access to
more trial data, but those data are not publicly available and
could not be included in our meta-analysis.
The extent of possible systematic bias is presented individually
in Table S9. It has been documented in a number of subfields of
veterinary health that failure to randomize and blind studies is
associated with biased estimates of intervention effects.
However, in two previous systematic reviews and network
meta-analyses related to BRD in beef cattle, we did not observe
any overall changes in the magnitude of intervention effects
(O’Connor et al., 2013, 2016). For some of the pairwise compar-
isons between antibiotics, Figs 4 and 5 show the relative contribu-
tions to the efficacy estimates of studies using different allocation
approaches and blinding approaches (Papakonstantinou et al.,
2018). Our approach to those contribution matrices is that they
should be used to interpret pairwise comparisons of particular
interest. For example, the estimate for the comparison of
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Fig. 4. The contributions to the point estimate of efficacy by studies using different allocation approaches: green indicates studies that provided evidence of ran-
dom allocation; yellow indicates studies that reported random allocation but provided no supporting evidence; red indicates studies that reported no allocation
approach or reported a non-random allocation approach. White vertical lines indicate the percentage contribution of separate studies. Each bar shows the per-
centage contribution from studies judged to be at low (green), moderate (yellow), and high (red) risk of bias.
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disease if OXY_1 is used instead of TMS. However, that estimate
is based on several non-randomized studies, as indicated by the
long red bar in Fig. 4, which also lacked information about
blinding (Fig. 5). The problem with interpreting that kind of
information is that, unlike in comparisons with placebos, we can-
not hypothesize the direction of bias, because the contribution
Fig. 5. The contributions to the point estimate of
efficacy by studies using different blinding
approaches: green indicates studies that provided
evidence of blinding of caregivers and outcome
assessors; yellow indicates studies that provided
evidence of blinding of either caregivers or out-
come assessors; red indicates studies that
reported no blinding of caregivers or outcome
assessors. White vertical lines indicate the per-
centage contribution of separate studies. Each
bar shows the percentage contribution from stud-
ies judged to be at low (green), moderate (yellow),
and high (red) risk of bias.
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information is based on a pathway rather than a study. We there-
fore propose that the contribution information provides a visual
indicator of the overall types of studies that contribute to a
given estimate. Making more specific inferences about the direc-
tion of bias would require more knowledge about particular stud-
ies. We might also be skeptical about the results because of the
sparse data, as indicated by the wide credible intervals. Although
the data and derived estimates of efficacy represent the best evidence
available, room for a healthy sense of uncertainty remains.
Limitations of the review process
Because our study was based on a systematic review, our first goal
was to identify the relevant literature. The search was extensive,
but it would have been ideal to have searched more databases if
resources had permitted. Our database searches were complemen-
ted by other search approaches, such as hand searching. The data-
base search strategies were sensitive, but they could have been
made more sensitive by making greater use of the AND operator
instead of the proximity operator, particularly to capture variant
phrases related to the metaphylaxis concept. However, available
resources dictated the use of the proximity operator since AND
reduced precision and generated an unmanageably large volume
of irrelevant records. It is also possible to search more websites
and search engines, such as Google Scholar. However, within
the limits of the available resources, we were able to achieve an
extensive search.
Overall, the studies that contributed to the evidence base for
our meta-analysis were well designed. Many studies reported ran-
domization of cattle among treatment groups even if they did not
provide evidence for the validity of the randomization. One of the
major issues that we uncovered was differences in the baseline
treatments that the cattle received when they arrived at the feedlot.
Those differences could be interpreted in two ways: first, that the
population was too heterogeneous to combine in a single analysis
or, second, that the heterogeneity reflects the underlying popula-
tion and is therefore a realistic representation of the cattle popu-
lation most likely to receive antibiotics.
Conclusions
Overall, the existing body of research suggests that injectable anti-
biotics are generally effective at controlling BRD in feedlot cattle
when they are administered at the time the cattle arrive at the
feedlot. There is evidence that macrolides are the most effective
injectable antibiotics for controlling BRD. The commonly used
injectable oxytetracycline is also effective at controlling BRD,
although less so than the macrolides. Oxytetracycline is already
commonly used in groups of feedlot cattle to control, and treat
BRD and therefore has advantages over the macrolides from an
antibiotic stewardship perspective. Therefore, there might be an
opportunity for wider use of injectable oxytetracycline to control
BRD in feedlot cattle. If the use of antibiotics in feedlot cattle is
discouraged, it is imperative that the efficacy of alternatives to
antibiotics are fully understood so that producers can plan to
mitigate the impacts that a lack of antibiotic use might have on
animal welfare, health, and production.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S1466252320000031.
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